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HE  TERM  “PUBLICATION  PLANNING”  CAN  
refer to a research group’s organizational time-
table and plan. Within the pharmaceutical in-
dustry, however, the term describes the finely calibrated 
process by which clinical trials, commentaries and other 
articles  supporting  the  efficacy  of  particular  products 
are written and released into the biomedical literature. 
This  article  describes  how  industry  uses  publication 
planning to sway medical and public opinion through 
the medium of medical journals.  
Industry publications describe the utility of publica-
tion planning in the following terms: it can “provide es-
sential, appropriate sources for other communications, 
whether promotional or scientific.”1 It may also “influ-
ence regulatory authorities globally” and “influence dis-
ease  perception  and  management  through  citation,  
discussion, and recommendation.”2 
The controlled production and release of pre-clinical 
studies, clinical trials, reviews and commentaries may 
begin  years  before  a  drug  is  launched  (Fig.  1).  Peer-
reviewed clinical efficacy studies supporting a new drug 
or a new indication for a commercially available drug 
are  considered  “primary”  or  “core”  publications.  Ac-
cording to an industry article, “For a pharma company, 
getting research published in a peer-reviewed medical 
journal  is  like  winning  a  stamp  of  approval  from  its 
most influential audience. It’s an automatic validation 
unmatched  by  any  other  medium.”2  Primary  articles 
“[p]rovide authoritative sources for marketing commu-
nications and other promotional materials,” “[s]upport 
the  positioning  and  selling  platform,  and  coordinate 
with the overall marketing plan” and “[a]ccelerate the 
adoption of a new chemical entity or new indication.”1 
In other words, they provide the foundation for subse-
quent  “secondary”  or  “derivative”  publications,  which 
include journal advertisements, promotional materials 
used by sales representatives, and reviews and opinion 
pieces published in medical journals.  
  Pharmaceutical companies cannot legally promote a 
drug  before  it  has  been  approved  by  a  regulatory 
authority, nor can they legally promote a marketed drug 
for off-label use (i.e., for indications other than those 
approved).  However,  the  US  Food  and  Drug  Admini-
stration (FDA) does not consider articles in the medical 
literature as promotional. As one industry article states, 
“Peer-reviewed  publications  offer  pharma  companies 
shelter from often-stormy regulatory waters. FDA views 
published  articles  as  protected  commercial  speech  so 
doesn’t regulate their content.”2 
For this reason, the generation of subtly persuasive 
opinion pieces that can be distributed to prescribers in 
the pages of medical journals is an extremely important 
component of publication planning. Sponsored articles 
can be difficult for journal editors and readers to spot. 
In  many  cases,  the  drug  that  the  article  is  meant  to 
promote is not even mentioned. For example, if a drug 
is the only treatment for a given condition, articles that 
review the prevalence, severity or complications of that 
condition will prepare the market by raising physician 
awareness of specific issues. Articles that highlight the 
inconvenience or risks of competing therapies increase 
receptivity  to  a  new  drug  that  is  more  convenient  or
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Figure 1: Publication planning and the lifecycle  
of a drug 
safer (e.g., has once-a-day dosing or is not associated with 
an adverse effect that may occur with competing drugs).  
Reviews  and  commentaries  are  the  Trojan  horses 
bearing these messages. To ensure that articles are well 
written  and  contain  suitably  subtle  marketing  mes-
sages, a pharmaceutical company may enlist the assis-
tance of a professional medical writer. Such assistance 
ranges from editing to ghostwriting (i.e., writing con-
tributed  by  authors  who  are  not  acknowledged  when 
the article is published). 
Medical  writers,  who  are  often  scientists  or  health 
professionals, are crucial to publication planning. They 
ensure that manuscripts are scientifically correct, pro-
fessional, organized, readable, persuasive and submit-
ted on time. Medical writers prepare primary and sec-
ondary publications, including clinical trial reports and 
reviews; they may also prepare meeting materials and 
abstracts.3 They may work directly for pharmaceutical 
companies, most often as freelancers, or they may be 
employed  by  medical  education  and  communications 
companies (MECCs), which derive most of their income 
from pharmaceutical companies.4  
A pharmaceutical company may create a publication 
plan internally or work with a MECC on the plan. The 
process described here is used to create secondary pub-
lications. Typically, a publication plan includes a time-
line  and  lists  of  articles,  grouped  under  specific  mes-
sages,  with  proposed  titles  and  journals  to  target  for 
submission (Fig. 2). Potential guest authors may also be 
listed.  
Once  the  topic  of  an  article  is  chosen,  a  medical 
writer generates an outline, which is approved by the 
sponsoring  pharmaceutical  company.  The  writer  then 
researches and writes the paper, incorporating the ap-
propriate  marketing  message;  an  experienced  writer 
may be able to communicate messages that align with a 
sponsor’s marketing objectives even when specific mes-
sages  are  not  provided. After  the  completed  article  is 
approved, a guest author, usually an academically affili-
ated  physician,  is  approached  by  the  sponsor.  Guest 
authors (who may receive payment through a MECC) 
are  generally  offered  the  option  to  contribute  to  or 
amend the article; they usually realize that edits disad-
vantageous to a sponsoring company’s marketing goals 
will result in the article not being published — or being 
published under another physician’s name.5   
After approving the article, the guest author submits 
the manuscript as his or her original work to a journal 
specified by the pharmaceutical company.  If the jour-
nal  asks  for  revisions  or  clarifications,  the  medical 
writer writes the response, again for the guest author’s 
signature.  
The  extent  of  medical  writers’  contributions  to  the 
medical literature is unknown. A limited study of 1000 
research articles in 10 international journals found that 
a medical writer was acknowledged in about 6% of the 
articles.6 In a recent case study, researchers examined 
internal  documents  belonging  to  Merck  that  were  re-
vealed during litigation related to rofecoxib, and linked 
these  documents  to  clinical  trials  and  review  articles 
published in medical journals. Of 20 rofecoxib clinical 
trial  manuscripts  that  were,  according  to  internal 
documents,  authored  by  Merck  scientists  or  medical 
writers, 16 gave an external, academically affiliated in-
vestigator first authorship position when they were sub-
sequently published in journals. Furthermore, 50 of 72 
review articles discussed within Merck prior to publica-
tion  were  published  as  solo-authored  articles  by  aca-
demic physicians, and only 2 of the coauthored articles 
attributed authorship to a Merck employee.7    
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    Figure 2: Publication planning 
 
Two organizations support those who work in publi-
cation planning. The mission of the International Publi-
cation Planning Association “is to foster excellence in 
medical  publications  and  communications  within  the 
biopharmaceutical  industry”;  according  to  its  website, 
the association “provides practical strategies for devel-
oping, implementing and executing an effective publica-
tion and communication plan as a critical component of 
the  clinical  biopharmaceutical  development  process. 
Our  aim  is  to  help  biopharmaceutical  communication 
executives and their agencies produce ethical and tar-
geted  publications  and  clinical  data  throughout  the 
product lifecycle.”8 The vision of the International Soci-
ety for Medical Publication Professionals (ISMPP) “is to 
be  the  recognized  and  respected  authority  for  the 
pharmaceutical, biotech, and device industries medical 
publication profession.”9  
Conclusion 
Publication  planning,  as  it  is  currently  practised  by 
pharmaceutical companies, can undermine the medical 
literature. Industry control over the timing, content and 
authorship of studies and opinion pieces including re-
views  and  commentaries  distorts  medical  discourse. 
That academic health professionals (physicians, nurses, 
pharmacists) lend their names to articles to which they 
may  have  contributed  nothing  is  ironic,  considering 
that such behaviour by students in the same academic 
institutions  would  be  considered  plagiarism.  The  
International Committee of Medical Journal Editors 
has published important criteria for authorship.10 Medical 
writers  are  highly  skilled  professionals  who  certainly 
should be acknowledged when they meet the criteria for 
authorship.  Disclosure,  however,  does  not  remove  com-
mercial  influence.  Sponsored  writing  reflects  sponsored 
messages. Even the most vigilant editor could not uncover 
all of the marketing messages embedded in manuscripts 
by publication planning professionals.  
We suggest that clinical trials sponsored by industry 
should be clearly labelled as such and sequestered from 
independent  studies  in  medical  journals.  Industry-
sponsored reviews and commentaries, including those 
sponsored through MECC intermediaries, should not be 
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Most peer-reviewed journals already require the dis-
closure  of  industry  sponsorship  for  the  publication  of 
clinical  trials  and  reviews.    However,  as  we  have  dis-
cussed,  it  is  difficult  to  discern  when  medical  writers 
have been involved.  
The  infiltration  of  the  medical  literature  by  undis-
closed sponsors using ghostwritten articles raises seri-
ous  ethical  issues.  The  medical  literature  should  be  a 
repository  of  reliable,  unbiased  scientific  studies  and 
considered  opinion.  Invisible  industry  influences  on 
publications and presentations undermine a vital foun-
dation for clinical decision-making.  
Perhaps further education of the academic and medi-
cal community about this practice and its ethical impli-
cations will lead to more critical review of manuscripts, 
and refusal of guest authorship invitations by academ-
ics and clinicians.   
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